Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...
Nasdaq

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy ...

RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related serious adverse events Biomarkers and measures of neurodevelopmental function from patients in Cohorts ...
BioWorld

Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo

Breaking News: Trump administration impacts continue to roil the life sciences sector Home » Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo ...
ascopubs.org

Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras

Expanded Access and Right To Try Requests: The Community Oncologist's Experience We hypothesized that because of availability of ICIs, systemic therapy use in the last 30 days of life (DOL) would have ...
BioWorld

Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo

Walking Fish Therapeutics Inc. presented a new first-in-class autologous B-cell therapy, named WFX-001, being developed for the treatment of Fabry disease.